Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties.

Mader M, de Dios A, Shih C, Bonjouklian R, Li T, White W, López de Uralde B, Sánchez-Martinez C, del Prado M, Jaramillo C, de Diego E, Martín Cabrejas LM, Dominguez C, Montero C, Shepherd T, Dally R, Toth JE, Chatterjee A, Pleite S, Blanco-Urgoiti J, Perez L, Barberis M, Lorite MJ, Jambrina E, Nevill CR Jr, Lee PA, Schultz RC, Wolos JA, Li LC, Campbell RM, Anderson BD.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):179-83. Epub 2007 Nov 1.

PMID:
18039577
2.

Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.

de Dios A, Shih C, López de Uralde B, Sánchez C, del Prado M, Martín Cabrejas LM, Pleite S, Blanco-Urgoiti J, Lorite MJ, Nevill CR Jr, Bonjouklian R, York J, Vieth M, Wang Y, Magnus N, Campbell RM, Anderson BD, McCann DJ, Giera DD, Lee PA, Schultz RM, Li LC, Johnson LM, Wolos JA.

J Med Chem. 2005 Apr 7;48(7):2270-3.

PMID:
15801819
3.

In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.

Schultz RM, Merriman RL, Andis SL, Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K, Powis G.

Anticancer Res. 1995 Jul-Aug;15(4):1135-9.

PMID:
7653991
4.

Advances with phospholipid signalling as a target for anticancer drug development.

Powis G, Berggren M, Gallegos A, Frew T, Hill S, Kozikowski A, Bonjouklian R, Zalkow L, Abraham R, Ashendel C, et al.

Acta Biochim Pol. 1995;42(4):395-403. Review.

5.

Atomic structure of the trypsin-A90720A complex: a unified approach to structure and function.

Lee AY, Smitka TA, Bonjouklian R, Clardy J.

Chem Biol. 1994 Oct;1(2):113-7.

PMID:
9383379
6.

A multisample assay for inhibitors of phosphatidylinositol phospholipase C: identification of naturally occurring peptide inhibitors with antiproliferative activity.

Hill SR, Bonjouklian R, Powis G, Abraham RT, Ashendel CL, Zalkow LH.

Anticancer Drug Des. 1994 Aug;9(4):353-61.

PMID:
7916901
7.

Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.

Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindey G, et al.

Cancer Res. 1994 May 1;54(9):2419-23.

8.

Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues.

Powis G, Gallegos A, Abraham RT, Ashendel CL, Zalkow LH, Grindey GB, Bonjouklian R.

Cancer Chemother Pharmacol. 1994;34(4):344-50.

PMID:
8033301
9.

A83016A, a new kinamycin type antibiotic.

Smitka TA, Bonjouklian R, Perun TJ Jr, Hunt AH, Foster RS, Mynderse JS, Yao RC.

J Antibiot (Tokyo). 1992 Apr;45(4):581-3. No abstract available.

10.

A83016F, a new member of the aurodox family.

Smitka TA, Bonjouklian R, Perun TJ Jr, Hunt AH, Boeck LV, Yao RC.

J Antibiot (Tokyo). 1992 Apr;45(4):433-43.

11.

Hypotensive properties of the protein kinase inhibitor, staurosporine, in normotensive and spontaneously hypertensive rats.

Secrest RJ, Williams P, Bonjouklian R, Modlin D, Firman K, Turk J, Cohen ML.

Clin Exp Hypertens A. 1991;13(2):219-34.

PMID:
2065465
12.

Synthesis and structure-activity relationships of new 9-N-alkyl derivatives of 9(S)-erythromycylamine.

Kirst HA, Wind JA, Leeds JP, Willard KE, Debono M, Bonjouklian R, Greene JM, Sullivan KA, Paschal JW, Deeter JB, et al.

J Med Chem. 1990 Nov;33(11):3086-94.

PMID:
2231610
13.

Studies of the antitumor activity of (2-alkoxyalkyl)- and (2-alkoxyalkenyl)phosphocholines.

Bonjouklian R, Phillips ML, Kuhler KM, Grindey GB, Poore GA, Schultz RM, Altom MG.

J Med Chem. 1986 Dec;29(12):2472-7.

PMID:
3783607
14.

Cyclic platelet-activating factor analogues derived from 2-deoxy-D-erythro-pentose.

Phillips ML, Bonjouklian R.

Carbohydr Res. 1986 Jan 15;146(1):89-96.

PMID:
3955572

Supplemental Content

Loading ...
Support Center